Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model

BACKGROUND: Nusinersen is approved for the treatment of spinal muscular atrophy. The most common approved dosing regimen is four intrathecal loading doses of nusinersen 12 mg; the first three are administered at 14-day intervals followed by a fourth dose 30 days later, and then 12-mg maintenance dos...

Descripción completa

Detalles Bibliográficos
Autores principales: MacCannell, Drew, Berger, Zdenek, Kirschner, Janbernd, Mercuri, Eugenio, Farrar, Michelle A., Iannaccone, Susan T., Kuntz, Nancy L., Finkel, Richard S., Valente, Marta, Muntoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790013/
https://www.ncbi.nlm.nih.gov/pubmed/35080757
http://dx.doi.org/10.1007/s40263-022-00899-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790013/
https://www.ncbi.nlm.nih.gov/pubmed/35080757
http://dx.doi.org/10.1007/s40263-022-00899-0

Ejemplares similares